Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: While clinical experience with left ventricular assist devices (LVAD) continues to grow and evolve, little is known regarding the ongoing use of certain medications in this population. We sought to evaluate the utility of digoxin in LVAD recipients and its association with outcomes.
Methods: A total of 505 patients who underwent continuous-flow LVAD implantation at 5 centers from 2007-2015 were included. Patients were divided into 4 groups: not on digoxin at any time (ND; n = 257), received digoxin pre implant (PreD; n = 144), received digoxin pre and post implant (ContD; n = 55), and received digoxin only post implant (PostD; n = 49). Survival and all-cause readmission were compared between the 4 groups.
Results: There was no difference in survival at 1 year nor at 3 years between groups (ND = 88%, 66%, respectively; PreD = 85%, 66%; ContD = 86%, 57%; PostD = 90%, 51%; p = 0.7). Readmission per 100 days also was not different between groups (ND = 0.5, PreD = 0.6, ContD = 0.5, PostD = 0.7; p = 0.1).
Conclusions: In this large, multicenter cohort, use of digoxin was not associated with any significant benefit in regard to mortality or hospitalization in patients supported with a continuous-flow LVAD. Importantly, its discontinuation post implant did not worsen all-cause hospitalization or survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876793 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0225628 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Surveillance of Digoxin Concentrations in Critically Ill Individuals with Heart Failure.
Medicina (Kaunas)
July 2025
Department of Anesthesiology and Intensive Therapy in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
Digoxin is a pharmacological agent of natural origin that is still occasionally administered in the intensive care unit (ICU). The objective of this study was to assess the efficacy of routine therapeutic drug monitoring (TDM) of digoxin in ICU patients with heart failure. This retrospective, single-center study was conducted using data from the ICU database of the Silesian Center for Heart Diseases in Zabrze, Poland.
View Article and Find Full Text PDFHerb-Drug Interaction Between Sailuotong and Pitavastatin: A Systematic Pharmacokinetic Investigation and Mechanism Analysis.
Drug Des Devel Ther
August 2025
Beijing Key Laboratory of Pharmacology of Chinese Materia Medica, Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, People's Republic of China.
Propose: Sailuotong (SLT), a standardized Chinese herbal preparation for vascular dementia (VaD), is frequently co-administered with pitavastatin (PIV). Potential herb-drug interactions (HDIs) between these agents remain uncharacterized. Given the high likelihood of using this combination to treat VaD, this study aims to systematically evaluate the effects of SLT on PIV's pharmacokinetics and elucidate underlying mechanisms.
View Article and Find Full Text PDFPredictive Value of Electrocardiographic Markers Versus Echocardiographic and Clinical Measures for Appropriate ICD Shocks in Heart Failure Patients.
J Clin Med
August 2025
Department of Cardiology, Hatay Mustafa Kemal University, Hatay 31060, Turkey.
Despite the survival benefit of ICDs in patients with HFrEF, most recipients do not receive appropriate therapy during follow-up. Existing risk models based on echocardiographic and clinical parameters show limited predictive accuracy for arrhythmic events. This study aimed to assess whether ECG-derived markers outperform conventional measures in predicting appropriate ICD shocks.
View Article and Find Full Text PDF[Retrospective analysis of the treatment of atrial fibrillation in a cardiological setting at cardiology institute of Abidjan (Côte d'Ivoire)].
Ann Cardiol Angeiol (Paris)
July 2025
Service de médecine de l'institut de cardiologie d'Abidjan (ICA), Côte d'Ivoire.
Objective: The aim of this study was to analyze the management of atrial fibrillation in a cardiology department in sub-Saharan Africa.
Methodology And Results: We conducted a retrospective study of 146 consecutive patients aged at least 18 years hospitalized for atrial fibrillation over a two-year period in our cardiology department at the cardiology institute of Abidjan (Côte d'Ivoire). The mean age of the study population was 61.
Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants.
Clin Pharmacokinet
September 2025
Innogen Pharmaceutical Co., Ltd., Shanghai, China.
Background: Efsubaglutide alfa, as a novel glucagon-like peptide-1 receptor agonist, was developed for the treatment of type 2 diabetes mellitus. Its effect on the rate and extent of absorption of concomitant oral medications (digoxin and metformin) was evaluated in healthy participants.
Methods: We conducted a single-center, open-label, fixed-sequence clinical trial involving 32 healthy participants who were assigned to either digoxin (N = 16) or metformin (N = 16) groups.